Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | POLA1 | P09884 | 1/20 | 0.71 |
| ▸ | POLD1 | P28340 | 1/20 | 0.71 |
| ▸ | TK1 | P04183 | 4/20 | 0.62 |
| ▸ | DTYMK | P23919 | 4/20 | 0.55 |
| ▸ | TYMS | P04818 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23635761 | 1.00 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL21579405 | 0.93 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL27102638 | 0.92 | POLB (0.72) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL24370822 | 0.92 | POLB (0.72) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL18844513 | 0.91 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL23934882 | 0.91 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL9600789 | 0.91 | POLB (0.71) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL9562911 | 0.90 | POLB (0.69) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL21555526 | 0.89 | POLB (0.69) | POLBPOLA1POLD1TK1DTYMK | |
| SCHEMBL22074478 | 0.89 | POLB (0.69) | POLBPOLA1POLD1TK1DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065461-B2 | Method for preparing 3′-O-amino-2′-deoxyribonucleoside-5′-triphosphate | DNA SCRIPT (FR) | 2024-08-20 | — | — | US | disclosed |
| US-20210214382-A1 | Method for Preparing 3'-O-Amino-2'-Deoxyribonucleoside-5'-Triphosphate | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-07-15 | — | — | US | disclosed |
| US-8212020-B2 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | BENNER STEVEN A | 2011-11-10 | — | — | US | disclosed |
| US-8034923-B1 | Reagents for reversibly terminating primer extension | BENNER STEVEN ALBERT | 2011-10-11 | — | — | US | disclosed |
| WO-2010110775-A1 | REAGENTS FOR REVERSIBLY TERMINATING PRIMER EXTENSION | BENNER STEVEN ALBERT (US) | 2010-09-30 | — | — | WO | disclosed |
| US-7544794-B1 | Method for sequencing DNA and RNA by synthesis | BENNER STEVEN ALBERT | 2009-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065461-B2 | Method for preparing 3′-O-amino-2′-deoxyribonucleoside-5′-triphosphate | NUDT1, TYMP, DUT | POLB 62/4885POLA1 253/4885POLD1 352/4885 |
| US-20110275124-A1 | Reagents for reversibly terminating primer extension | RNGTT, POLRMT, DNTT | POLB 28/4885POLA1 56/4885POLD1 161/4885 |
| US-20210214382-A1 | Method for Preparing 3'-O-Amino-2'-Deoxyribonucleoside-5'-Triphosphate | NUDT1, TYMP, NT5C3B | POLB 63/4885POLA1 250/4885POLD1 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.